Citigroup
SVA

Citigroup’s Sinovac Biotech, Ltd SVA Stock Holding History

Citigroup’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-187
Closed -$1K – 7755
2017
Q1 		$1K Sell
187
-1,424
-88% -$8.24K ﹤0.01% 7160
2016
Q4 		$10K Sell
1,611
-107,587
-99% -$647K ﹤0.01% 6766
2016
Q3 		$644K Sell
109,198
-174,307
-61% -$1.03M ﹤0.01% 3666
2016
Q2 		$1.68M Hold
283,505
– – ﹤0.01% 2472
2016
Q1 		$1.81M Buy
+283,505
New +$1.7M ﹤0.01% 2617
2015
Q4 		– Sell
-8,109
Closed -$41K – 8354
2015
Q3 		$41K Sell
8,109
-89
-1% -$471 ﹤0.01% 5570
2015
Q2 		$43K Buy
8,198
+928
+13% +$4.9K ﹤0.01% 5638
2015
Q1 		$36K Sell
7,270
-4,354
-37% -$21.4K ﹤0.01% 5748
2014
Q4 		$61K Buy
11,624
+4,968
+75% +$25.3K ﹤0.01% 5568
2014
Q3 		$32K Buy
6,656
+1,671
+34% +$8.97K ﹤0.01% 5612
2014
Q2 		$28K Sell
4,985
-10,730
-68% -$65.2K ﹤0.01% 5629
2014
Q1 		$113K Buy
15,715
+8,198
+109% +$54.3K ﹤0.01% 4884
2013
Q4 		$46K Sell
7,517
-21,274
-74% -$128K ﹤0.01% 5770
2013
Q3 		$172K Buy
28,791
+9,739
+51% +$46.6K ﹤0.01% 4285
2013
Q2 		$74K Buy
+19,052
New +$70.9K ﹤0.01% 5105

Other funds holding SVA

SA
SAIF Advisors Admiralty, Hong Kong $438M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citigroup's SVA Position: Q2 2017 in Review

Citigroup sold out of Sinovac Biotech, Ltd (SVA) in Q2 2017, closing a stake of 187 shares — an estimated $1K sold.

Citigroup first reported a position in SVA in Q2 2013 and held it in 15 quarters. The position peaked at $1.81M in Q1 2016. 37 funds tracked by Wall St. Rank hold SVA as of Q2 2017.

  • Citigroup reported no remaining Sinovac Biotech, Ltd position as of Q2 2017 after selling out during the quarter.
  • Citigroup sold 187 Sinovac Biotech, Ltd shares in Q2 2017, an estimated $1K.
  • Citigroup first reported a position in Sinovac Biotech, Ltd in Q2 2013 and held it in 15 quarters.
  • Citigroup's Sinovac Biotech, Ltd position peaked at $1.81M in Q1 2016.
  • 37 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2017.

Based on Citigroup's 13F filing for Q2 2017, filed 11 Aug 2017.